{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-109979","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2026-09-23T20:17:30+00:00","discovered_at":"2026-09-23T20:19:09.193002+00:00","generated_at":"2026-09-23T20:19:36.807880+00:00","sec_items":["1.01","2.01","3.01","3.03","5.01","5.02","5.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Theravance completes $17/share cash-plus-CVR merger with Zymeworks; delists from Nasdaq","bullets":["Merger closed Sept 23, 2026: each TBPH share converted to $17.00 cash plus one contingent value right (CVR).","CVR pays 80% of net ampreloxetine license proceeds within 10 years, $50M milestone on first US/UK/Spain/France/Germany/Italy sale, and 10% of net sales.","CEO Rick Winningham and all six directors resigned at closing; Kristin Stafford, Scott Platshon, Paul Schneider appointed as new directors.","Ordinary shares delisted from Nasdaq; Form 25 to be filed with deregistration via Form 15 planned.","Merger financed by Zymeworks through cash on hand plus new debt financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-109979","json":"https://secwatch.observer/filing/0001104659-26-109979.json","markdown":"https://secwatch.observer/filing/0001104659-26-109979.md","text":"https://secwatch.observer/filing/0001104659-26-109979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926109979/0001104659-26-109979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926109979/tm2625984d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-23T20:19:36.807880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}